Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs

Wang, Wusan; Ji, Hui; Li, Tingting; Jia, Yuanwei; Xie, Haitang

doi:10.1515/acph-2016-0013

Abstract

A pharmacokinetic comparison and conformational stability study of S-oxiracetam (S-ORT) and R-oxiracetam (R-ORT) in beagle dogs was used to investigate the possible mechanism of different effects of two oxiracetam enantiomers through a random crossover design. After drug administration to beagle dogs, blood samples were collected at different time points for pharmacokinetic analysis using the UPLC-ESI-MS/MS method. Parts of plasma samples were used for conformation transformation studies using a normal phase high performance liquid chromatographic (NP HPLC) method. The study showed that oxiracetam enantiomers maintained their original conformation when administered orally to beagle dogs. Concentrations of S-ORT were significantly higher than R-ORT 1.5 and 2 h after administration; the AUC_0-∞ of S-ORT after oral administration tended to be higher than that of R-ORT, which showed that the different effects between S-ORT and R-ORT may be partly associated with their distinctive absorption at least.

References

1. Z. Hlinak, J. Vinsova and E. Kasafirek, Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice, Eur. J. Pharmacol.314 (1996) 1–7.10.1016/S0014-2999(96)00485-2
Search in Google Scholar
2. Z. Hlinak and I. Krejci, Oxiracetam pre-but not post-treatment prevented social recognition deficits produced with trimethyltin in rats, Behav. Brain Res.161 (2005) 213–219; DOI: 10.1016/j.bbr.2005.02.030.10.1016/j.bbr.2005.02.030
Search in Google Scholar
3. C. Mondadori, B. Hengerer, T. Ducret and J. Borkowski, Delayed emergence of effects of memoryenhancing drugs: implications for the dynamics of long-term memory, Proc. Natl. Acad. Sci. USA91 (1994) 2041–2045.10.1073/pnas.91.6.2041
Search in Google Scholar
4. C. Mondadori, H. J. Möbius and J. Borkowski, The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory, Behav. Brain Res. 77 (1996) 223–225.10.1016/0166-4328(95)00222-7
Search in Google Scholar
5. W. H. Brooks, W. C. Guida and K. G. Daniel, The significance of chirality in drug design and development, Curr. Top. Med. Chem. 11 (2011) 760–770; DOI: 10.2174/156802611795165098.10.2174/156802611795165098
Search in Google Scholar
6. A. J. Hutt, Chirality and pharmacokinetics: an area of neglected dimensionality, Drug Metabol. Drug Interact. 22 (2007) 79–112; DOI: 10.1515/DMDI.2007.22.2-3.79.10.1515/DMDI.2007.22.2-3.79
Search in Google Scholar
7. T. Kolev, M. Spiteller and B. Koleva, Spectroscopic and structural elucidation of amino acid derivatives and small peptides: experimental and theoretical tools, Amino Acids38 (2010) 45–50; DOI: 10.1007/s00726-008-0220-9.10.1007/s00726-008-0220-9
Search in Google Scholar
8. H. Lu, Stereoselectivity in drug metabolism, Expert Opin. Drug Metab. Toxicol. 3 (2007) 149–158; DOI: 10.1517/17425255.3.2.149.10.1517/17425255.3.2.149
Search in Google Scholar
9. Q. Shen, L. Wang, H. Zhou, L. S. Yu and S. Zeng, Stereoselective binding of chiral drugs to plasma proteins, Acta Pharmacol. Sinica34 (2013) 998–1006; DOI: 10.1038/aps.2013.78.10.1038/aps.2013.78
Search in Google Scholar
10. N. Inotsume and M. Nakano, Stereoselective determination and pharmaco-kinetics of dihydropyridines: an updated review, J. Biochem. Biophys. Methods54 (2002) 255–274; DOI: 10.1016/S0165-022X(02)00120-3.10.1016/S0165-022X(02)00120-3
Search in Google Scholar
11. R. Mehvar and D. R. Brocks, Stereospecific pharmacokinetics and pharmacodynamics of betaadrenergic blockers in humans, J. Pharm. Pharm. Sci. 4 (2001) 185–200.
Search in Google Scholar
12. L.A. Nguyen, H. He and C. Pham-Huy, Chiral drugs: an overview, Int. J. Biomed. Sci.2 (2006) 85–100.
Search in Google Scholar
13. L. Chiodini, G. Pepeu, Composition Comprising S-oxiracetame for Use as Nootropic, EP. WO 1,993,006,826 A1, 15 April 1993; ref. Chem. Abstr. 119 (1993) 139083.
Search in Google Scholar
14. W. S. Wang, H. Ji, H. T. Xie, M. Dai, Y. W. Jia, D. H. Liang, L. Ye and Z. Y. Rong, A sensitive and specific UPLC–MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in beagle dogs, Chin. J. Clin. Pharmacol Ther. 17 (2012) 988–994.
Search in Google Scholar
15. J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, W. Theobald, G. Reumond and H. Beck, Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with nongeriatric healthy subjects, Eur. J. Drug Metab. Pharmacokinet.15 (1990) 223–237.10.1007/BF031902082253653
Search in Google Scholar
16. E. Perucca, A. Albrici, G. Gatti, R. Spalluto, M. Visconti and A. Crema, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers, Eur. J. Drug Metab. Pharmacokinet. 9 (1984) 267–274.10.1007/BF031896506519128
Search in Google Scholar
17. E. Perucca, J. Parini, A. Albrici, M. Visconti and E. Ferrero, Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly, Eur. J. Drug Metab. Pharmacokinet.12 (1987) 145148.
Search in Google Scholar
18. X. Wan, H. Wang, P. Ma, L. Xi, J. Sun, Z. He, X. Zhang and X. Liu, Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC–MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration, J. Chromatogr. B. 969 (2014) 95–100; DOI: 10.1016/j.jchromb.2014.07.041.10.1016/j.jchromb.2014.07.04125168792
Search in Google Scholar

Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs

Abstract

Paradigm

My account